VNRX
VOLITIONRX LTD
Key Financials
Operating Income
$-21738571
↑ 19.6%
Revenue
$1.7M
↑ 40.0%
Net Income
$-23357027
↑ 14.3%
EPS (Diluted)
$-0.31
↑ 38.0%
Shareholders' Equity
$-34246393.00
↓ 37.5%
Total Assets
$6.9M
↓ 26.6%
Total Liabilities
$42.5M
↑ 19.7%
Cash & Equivalents
$1.1M
↓ 65.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| 8-K | 7/21/2026 | View on SEC |
| EFFECT | 7/17/2026 | View on SEC |
| S-3 | 7/10/2026 | View on SEC |
| 8-K | 6/18/2026 | View on SEC |
| 8-K | 6/10/2026 | View on SEC |
| 424B5 | 6/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VNRX |
| Company Name | VOLITIONRX LTD |
| CIK | 93314 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 1 (512) 774-8930 |